5 research outputs found

    El daño ocasionado por las omisiones legislativas y convencionales : el daño antijurídico causado a las parejas del mismo sexo por la no regulación del matrimonio

    Get PDF
    El presente trabajo tuvo por objeto establecer cómo es que las omisiones legislativa y convencional generan un daño antijurídico. Para el efecto, se estudió la no regulación del matrimonio para parejas del mismo sexo en Colombia y los supuestos reconocidos por las sentencias C – 577 de 2011 y SU – 214 de 2016 proferidas por la Corte Constitucional colombiana, con el propósito de establecer no sólo la constitución de las omisiones legislativa relativa y convencional en atención al supuesto normativo del artículo 113 del Código Civil colombiano; sino que, además, cómo es que dichas pretermisiones habrían causado un daño antijurídico a todas aquellas personas que no pudieron contraer nupcias con personas de su mismo sexo, en atención a las garantías de fuente normativa diversa que radican en su cabeza y por el simple hecho de pertenecer a la especie humana.The main objective of this paper was to establish how legislative and conventional omissions generate anti-legal damage. For this purpose, the lack of laws pertaining to same-sex marriage in Colombia and the assumptions recognized by judgments C - 577 of 2011 and SU - 214 of 2016 issued by the Colombian Constitutional Court were studied, with the purpose of establishing not only the relative constitution and legislative omission, with respect to the normative 113 of the Colombian Civil Code; but, in addition In view of the negative effect that could have prevented same sex couples to wed.MaestríaMagíster en Derecho Privado, Persona y Sociedad con énfasis en Responsabilidad Contractual y Extracontractual Civil y del Estad

    Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study

    Get PDF
    Background Huntington's disease is caused by a CAG repeat expansion in the huntingtin gene, HTT. Age at onset has been used as a quantitative phenotype in genetic analysis looking for Huntington's disease modifiers, but is hard to define and not always available. Therefore, we aimed to generate a novel measure of disease progression and to identify genetic markers associated with this progression measure. Methods We generated a progression score on the basis of principal component analysis of prospectively acquired longitudinal changes in motor, cognitive, and imaging measures in the 218 indivduals in the TRACK-HD cohort of Huntington's disease gene mutation carriers (data collected 2008–11). We generated a parallel progression score using data from 1773 previously genotyped participants from the European Huntington's Disease Network REGISTRY study of Huntington's disease mutation carriers (data collected 2003–13). We did a genome-wide association analyses in terms of progression for 216 TRACK-HD participants and 1773 REGISTRY participants, then a meta-analysis of these results was undertaken. Findings Longitudinal motor, cognitive, and imaging scores were correlated with each other in TRACK-HD participants, justifying use of a single, cross-domain measure of disease progression in both studies. The TRACK-HD and REGISTRY progression measures were correlated with each other (r=0·674), and with age at onset (TRACK-HD, r=0·315; REGISTRY, r=0·234). The meta-analysis of progression in TRACK-HD and REGISTRY gave a genome-wide significant signal (p=1·12 × 10−10) on chromosome 5 spanning three genes: MSH3, DHFR, and MTRNR2L2. The genes in this locus were associated with progression in TRACK-HD (MSH3 p=2·94 × 10−8 DHFR p=8·37 × 10−7 MTRNR2L2 p=2·15 × 10−9) and to a lesser extent in REGISTRY (MSH3 p=9·36 × 10−4 DHFR p=8·45 × 10−4 MTRNR2L2 p=1·20 × 10−3). The lead single nucleotide polymorphism (SNP) in TRACK-HD (rs557874766) was genome-wide significant in the meta-analysis (p=1·58 × 10−8), and encodes an aminoacid change (Pro67Ala) in MSH3. In TRACK-HD, each copy of the minor allele at this SNP was associated with a 0·4 units per year (95% CI 0·16–0·66) reduction in the rate of change of the Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score, and a reduction of 0·12 units per year (95% CI 0·06–0·18) in the rate of change of UHDRS Total Functional Capacity score. These associations remained significant after adjusting for age of onset. Interpretation The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation

    Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

    Get PDF
    Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective

    Grado de implementación de las estrategias preventivas del síndrome post-UCI: estudio observacional multicéntrico en España

    No full text
    corecore